Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach

Christos Fotis, Nikolaos Meimetis, Nikos Tsolakos, Marianna Politou, Karolina Akinosoglou, Vicky Pliaka, Angeliki Minia, Evangelos Terpos, Ioannis P. Trougakos, Andreas Mentis, Markos Marangos, George Panayiotakopoulos, Meletios A. Dimopoulos, Charalampos Gogos, View ORCID ProfileAlexandros Spyridonidis, Leonidas G. Alexopoulos
doi: https://doi.org/10.1101/2020.09.09.20191122
Christos Fotis
1Biomedical Systems Laboratory, National Technical University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaos Meimetis
1Biomedical Systems Laboratory, National Technical University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikos Tsolakos
2ProtATonce Ltd, Demokritos Science Park, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianna Politou
3Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karolina Akinosoglou
4Department of Internal Medicine, Division of Infectious Diseases, University Hospital of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicky Pliaka
2ProtATonce Ltd, Demokritos Science Park, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angeliki Minia
2ProtATonce Ltd, Demokritos Science Park, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evangelos Terpos
3Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis P. Trougakos
5Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Mentis
6Medicinal Microbiology Laboratory, Hellenic Pasteur Institute, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markos Marangos
4Department of Internal Medicine, Division of Infectious Diseases, University Hospital of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Panayiotakopoulos
7Pharmacology Laboratory, University of Patras, Patras, Greece
8National Public Health Organization, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meletios A. Dimopoulos
3Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charalampos Gogos
4Department of Internal Medicine, Division of Infectious Diseases, University Hospital of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandros Spyridonidis
9Department of Internal Medicine, BMT Unit and CBMDP Donor Center, University of Patras, Patras, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandros Spyridonidis
  • For correspondence: leo@mail.ntua.gr spyridonidis@upatras.gr
Leonidas G. Alexopoulos
1Biomedical Systems Laboratory, National Technical University of Athens, Athens, Greece
2ProtATonce Ltd, Demokritos Science Park, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: leo@mail.ntua.gr spyridonidis@upatras.gr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

More than 300 SARS-COV-2 serological tests have recently been developed using either the nucleocapsid phosphoprotein (N), the spike glycoprotein subunit (S1), and more recently the receptor binding domain (RBD). Most of the assays report very good clinical performance characteristics in well-controlled clinical settings. However, there is a growing belief that good performance characteristics that are obtained during clinical performance trials might not be sufficient to deliver good diagnostic results in population-wide screens that are usually characterized with low seroprevalence. In this paper, we developed a serological assay against N, S1 and RBD using a bead-based multiplex platform and a rules-based computational approach to assess the performance of single and multi-antigen readouts in well-defined clinical samples and in a population-wide serosurvey from blood donors. Even though assays based on single antigen readouts performed similarly well in the clinical samples, there was a striking difference between the antigens on the population-wide screen. Asymptomatic individuals with low antibody titers and sub-optimal assay specificity might contribute to the large discrepancies in population studies with low seroprevalence. A multi-antigen assay requiring partial agreement between RBD, N and S1 readouts exhibited enhanced specificity, less dependency on assay cut-off values and an overall more robust performance in both sample settings. Our data suggest that assays based on multiple antigen readouts combined with a rules-based computational consensus can provide a more robust platform for routine antibody screening.

One Sentence Summary Clinical and Population-level performance of single and multiplex SARS-CoV-2 serological assays.

Competing Interest Statement

LGA, NT, AM VP, are members of ProtATonce Ltd. All other authors declare no competing interests related to this article.

Funding Statement

FUNDING: Does not apply.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Sampling from SARS-CoV-2 positive individuals was done with informed consent and under approved institutional and ethic review board approved clinical protocols conducted in full compliance with the principles of Good Clinical Practice and the Declaration of Helsinki (University Hospital of Patras EC 164/27.04.2020 and IRB 216/08.05.2020, Alexandra General Hospital NCT04408209 trial). Stored negative samples were acquired in accordance with local ethical approvals. The population-level study was approved by the Research Ethics Committee of the University of Patras (Ref. Number 6099) and all participants gave written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 10, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach
Christos Fotis, Nikolaos Meimetis, Nikos Tsolakos, Marianna Politou, Karolina Akinosoglou, Vicky Pliaka, Angeliki Minia, Evangelos Terpos, Ioannis P. Trougakos, Andreas Mentis, Markos Marangos, George Panayiotakopoulos, Meletios A. Dimopoulos, Charalampos Gogos, Alexandros Spyridonidis, Leonidas G. Alexopoulos
medRxiv 2020.09.09.20191122; doi: https://doi.org/10.1101/2020.09.09.20191122
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach
Christos Fotis, Nikolaos Meimetis, Nikos Tsolakos, Marianna Politou, Karolina Akinosoglou, Vicky Pliaka, Angeliki Minia, Evangelos Terpos, Ioannis P. Trougakos, Andreas Mentis, Markos Marangos, George Panayiotakopoulos, Meletios A. Dimopoulos, Charalampos Gogos, Alexandros Spyridonidis, Leonidas G. Alexopoulos
medRxiv 2020.09.09.20191122; doi: https://doi.org/10.1101/2020.09.09.20191122

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)